Evaluation of the clinical performance of the cobas® 4800 1 HPV test in a colposcopy referred population
Files in This Item:
|Evaluation_of_the_clinical_performance_of_the_cobas®_4800_HPV_test_in_a_colposcopy_referred_population.pdf||426.39 kB||Adobe PDF||Download|
|Title:||Evaluation of the clinical performance of the cobas® 4800 1 HPV test in a colposcopy referred population||Authors:||White, Christine
O'Leary, John J.
Martin, Cara M.
|Permanent link:||http://hdl.handle.net/10197/9202||Date:||Oct-2013||Abstract:||The clinical performance of the cobas human papillomavirus (HPV) test for detection of high-grade disease in a colposcopy-referred population was compared with that of Hybrid Capture 2 (HC2). The overall agreement between the tests was 92.3%. Clinical sensitivity and specificity for detection of cervical intraepithelial neoplasia grade 2 or greater (CIN2+) were 90.0% and 55.5% for cobas and 90.5% and 50.2% for HC2, respectively. In conclusion, both tests showed comparable performance for detection of CIN2+.||Funding Details:||Health Research Board||Type of material:||Journal Article||Publisher:||American Society for Microbiology||Journal:||European Journal of Clinical Microbiology||Volume:||51||Issue:||10||Start page:||3415||End page:||3417||Copyright (published version):||2013 American Society for Microbiology||Keywords:||Virology||DOI:||10.1128/JCM.01949-13||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Medicine Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.